RDUS wayyy oversold on news of new CEO - sell puts/enter!

18 Tem 2017

RDUS still maintains analyst buys/PT of >60 wth their new approved drug, Tymlos which will start selling later this year (hopefully) and has strong advantages over current Forteo. Nevertheless, the market wayyyy overreacted to news of a new CEO & look at the RSI now! I just wrote Jan 2018 35 puts and about to write July & Aug. 40s for easy premium or cheap shares (couldn't resist despite being farther out than i normally write them)...DEF recommend selling puts on this one or grabbing your first 1/3 position for easy swing or hold back to 50 in short order!